Compare Gold Fields Limited (GFI) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs Tango Therapeutics Inc. — how do they compare? Gold Fields Limited trades at $36.68 (market cap $32.51B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Gold Fields Limited is far larger — about 8.7× Tango Therapeutics Inc.'s market cap, and Gold Fields Limited pays a 5.92% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gold Fields Limited for 50 Days and Tango Therapeutics Inc. for 0 Days on average.
| GFI | TNGX | |
|---|---|---|
Market Cap | $32.51B | $3.75B |
Volume | 3,490,155 | 9,619,106 |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $32.90 |
52-Week Low | $31.25 | $7.50 |
Typical Hold Time | 50 Days | 0 Days |
Enterprise Value | $33.11B | $2.77B |
Dividend Yield | 5.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $35.55, down 3.29% amid market reaction to its rejected $27 billion bid for Northern Star. Despite recent earnings misses, the company shows strong fundamentals with a low P/E of 7.4, robust net income margin of 38.66%, and record 2025 revenue of $8.75 billion. Technical indicators are bearish, with the stock near key support at $36. Analyst consensus remains positive with a $52.75 price target, though sentiment is cautious due to acquisition uncertainty.
The outlook for GFI is mixed; its undervalued metrics and high profitability support upside potential, but near-term volatility from the failed acquisition and bearish technicals pose risks. Investors should weigh the company's strong cash flow generation and growth prospects against execution risks and gold price sensitivity.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
